SEOM clinical guidelines for endometrial cancer (2017)
Open Access
- 13 December 2017
- journal article
- research article
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 20 (1) , 29-37
Abstract
Endometrial cancer (EC) is the most common gynecological cancer in developed countries. Most patients are diagnosed at an early stage with a low risk of relapse. However, there is a group of patients with a high risk of relapse and poor prognosis. Despite the recent publication of randomized trials, the adjuvant treatment of high-risk EC is still to be defined and there are many open questions about the best approach and the right timing. Unfortunately, the survival of metastatic or recurrent EC is short, due to the poor results of chemotherapy and the lack of a second line of treatment. Advances in the knowledge of the molecular abnormalities in EC have permitted the development of promising targeted therapies.Keywords
This publication has 23 references indexed in Scilit:
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Cancer Risks forMLH1andMSH2Mutation CarriersHuman Mutation, 2013
- Molecular pathology of endometrial carcinomaHistopathology, 2012
- Revised FIGO Staging System for Endometrial CancerClinical Obstetrics and Gynecology, 2011
- Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer – Results from two randomised studiesEuropean Journal of Cancer, 2010
- Intravaginal Brachytherapy in FIGO Stage I Low-Risk Endometrial CancerInternational Journal of Gynecological Cancer, 2009
- Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised studyThe Lancet, 2009
- Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical TrialJNCI: Journal of the National Cancer Institute, 2008
- Hormone therapy in advanced and recurrent endometrial cancer: a systematic reviewInternational Journal of Gynecological Cancer, 2007
- Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2004